Life Sciences Tools and Services

TAILIN BIOTECH

TAILIN BIOTECH FY2026 Q1 Earnings Release on April 28 After-Market (BJT)

TAILIN BIOTECH released FY2025 Q4 earnings on March 26 After-Market (BJT), actual revenue CNY 126.35 M, actual EPS CNY 0.0171

TAILIN BIOTECH released FY2025 Annual Earnings on March 26 After-Market (BJT), with actual revenue of CNY 339.54 M and actual EPS of CNY 0.14

TAILIN BIOTECH FY2025 Earnings Release Scheduled for March 27, 2026 After-Market BJT

TAILIN BIOTECH released FY2025 9 Months Earnings on October 26 After-Market (BJT), actual revenue CNY 213.19 M, actual EPS CNY 0.1154

TAILIN BIOTECH released FY2025 Q3 earnings on October 26 After-Market (BJT), actual revenue CNY 67.36 M, actual EPS CNY 0.0075

TAILIN BIOTECH to Release FY2025 Q3 Earnings on October 27 After-Market BJT

TAILIN BIOTECH released FY2025 Q2 earnings on August 28 Pre-Market BJT, actual revenue CNY 78.89 M, actual EPS CNY 0.0778

TAILIN BIOTECH released FY2025 Semi-Annual Earnings on August 28 Pre-Market (BJT), actual revenue CNY 145.83 M, actual EPS CNY 0.11

TAILIN BIOTECH to Release FY2025 Semi-Annual Earnings on August 29, 2025 (BJT)

Taibios Holding Shareholder's Reduction Plan

Taibio New Materials Acquires Land Through Auction for Funding Projects

Taibio Increases Capital in Wholly-Owned Subsidiary to Support New Project

Talin Bio's Subsidiary Signs 300 Million Yuan Project with Fuchunwan New City

Taibio Announces Q1 2025 Report Showing Revenue and Profits Declining

TAILIN BIOTECH released FY2024 Q4 earnings on April 27 After-Market BJT, actual revenue CNY 106.53 M, actual EPS CNY 0.0181

TAILIN BIOTECH released FY2024 Annual Earnings on April 27 After-Market (BJT), actual revenue CNY 349 M, actual EPS CNY 0.12

TAILIN BIOTECH released FY2025 Q1 earnings on April 27 After-Market (BJT), actual revenue CNY 66.94 M, actual EPS CNY 0.03

TAILIN BIOTECH to Release FY2025 Q1 Earnings Report on April 28 After-Market BJT

TAILIN BIOTECH FY2024 Earnings Release Scheduled for April 28, 2025 After-Market BJT

300813

TAILIN BIOTECH released its third-quarter report for 2025, with operating revenue of 213 million yuan in the first three quarters, a year-on-year decrease of 12.08%. The net profit attributable to shareholders of the listed company was 14.7233 million yuan, a year-on-year increase of 30.13%. The net profit after deducting non-recurring gains and losses was 13.0487 million yuan, a year-on-year increase of 21.83%. The basic earnings per share were 0.12 yuan

Zhitong

TAILIN BIOTECH released its performance for the first three quarters, with a net profit attributable to the parent company of 14.7233 million yuan, an increase of 30.13%

TAILIN BIOTECH announced that GaoDe Investment will reduce its holdings by 1.2118 million shares and 600,000 shares through centralized bidding and block trading respectively from August 8, 2025, to October 15, 2025, with a reduction price range of 24.35-42.01 yuan/share and a block trading price of 27.69 yuan/share, totaling a reduction of 1.8118 million shares, accounting for 1.4949% of the company's total share capital; after the reduction, the holdings will be 5.4663 million shares, accounting for 4.51%

TAILIN BIOTECH: GaoDe Investment has reduced its holdings by 1.4949%

TAILIN BIOTECH announced that its wholly-owned subsidiary, Tailin Medical Devices, recently obtained a utility model patent certificate. The patent is titled "An Automated Device for Microbial Limit Testing," with application number 2024218453749, and the authorization announcement date is September 5, 2025. The acquisition of this patent will not have a significant impact on recent production and operations, but it is beneficial for the company to further improve its intellectual property protection system, leverage its independent intellectual property advantages, establish a continuous innovation mechanism, and enhance its core competitiveness

TAILIN BIOTECH: Obtained 1 patent certificate

TAILIN BIOTECH released its 2025 semi-annual report, with operating revenue of 146 million yuan, a year-on-year decrease of 6.69%. The net profit attributable to shareholders was 13.5429 million yuan, a year-on-year increase of 105.76%. The net profit after deducting non-recurring gains and losses was 13.2038 million yuan, a year-on-year increase of 116.80%. The basic earnings per share were 0.11 yuan, and it plans to distribute a cash dividend of 1 yuan (including tax) for every 10 shares to all shareholders

TAILIN BIOTECH released its performance for the first half of the year, with a net profit attributable to the parent company of 13.5429 million yuan, an increase of 105.76%

300887

002030

300012

The food safety concept has rebounded sharply, with DAJY hitting the daily limit, followed by gains in Litong Technology, PONY, Shipu Testing, TAILIN BIOTECH, CTI, and Zhijiang Biology

PONY

DAJY

The food safety concept has rebounded sharply, and DAJY has hit the daily limit

TAILIN BIOTECH announced that its controlling shareholder's concerted actor, Gaode Investment, plans to reduce its holdings by no more than 1.8195 million shares, accounting for 1.5% of the company's total share capital, within 15 trading days after the announcement, through methods such as centralized bidding or block trading

TAILIN BIOTECH: GaoDe Investment plans to reduce its holdings by no more than 1.5% of shares

TAILIN BIOTECH announced that Mr. Ye Dalin, the company's controlling shareholder and actual controller, has completed the transfer of 12.1 million shares to Ms. Ni Weiju through a negotiated transfer on July 15, 2025. Ms. Ni Weiju has committed not to actively reduce her holdings of the shares obtained from this transfer in any way within 12 months from the completion of the transfer. This transfer does not involve any reduction in the secondary market and will not lead to a change in the company's controlling shareholder and actual controller

TAILIN BIOTECH's controlling shareholder has completed the transfer and registration of 12.1 million shares

TAILIN BIOTECH obtained the land use rights for a plot of land in Fuyang District, Hangzhou through bidding, with a transfer price of 15.79 million yuan. This plot will be used to implement the company's fundraising project "High-Performance Filter and Supporting Functional Membrane Industrialization Project."

FORTUNE SUN

TAILIN BIOTECH bids for a land plot to implement the industrialization project of high-performance filters and supporting functional membranes

TAILIN BIOTECH announced that the company has decided to increase its investment in its wholly-owned subsidiary, Zhejiang Tailin New Materials Co., Ltd., by 109 million yuan to meet the funding needs of the new project "High-Performance Filter and Supporting Functional Membrane Industrialization Project." Of the increased investment, 90 million yuan will be included in the registered capital, and the remaining amount will be included in the capital reserve. After the increase, the registered capital of Tailin New Materials will rise from 10 million yuan to 100 million yuan, and it will still be a wholly-owned subsidiary of the company

TAILIN BIOTECH: Increased capital by 109 million yuan to wholly-owned subsidiary

On the evening of April 27th, TAILIN BIOTECH announced that its wholly-owned subsidiary, Zhejiang Tailin New Materials Co., Ltd., intends to sign the "High-Performance Filter and Supporting Functional Membrane Industrialization Project Contract" with the Hangzhou Fuchun Bay New Town Management Committee, to invest in and construct the "Zhejiang Tailin New Materials Co., Ltd. High-Performance Filter and Supporting Functional Membrane Industrialization Project" in Hangzhou Fuchun Bay New Town, with a total investment of no less than 300 million yuan

TAILIN BIOTECH: Subsidiary plans to invest no less than 300 million yuan to build a high-performance filter and supporting functional membrane industrialization project

TAILIN BIOTECH(300813.SZ)